Who was studied?
35 patients with advanced refractory malignancies treated at the First Affiliated Hospital of Guangxi Medical University.
What does the publication report?
ORR was 14% and DCR 43%; median PFS was 4.0 months and median OS 10.0 months.
Safety findings
Grade 3 treatment-related adverse events occurred in 2 patients (6%) and grade 4 events in 1 patient (3%).
How should we interpret it?
A small non-randomized cohort without a control arm; institutional affiliation is the First Affiliated Hospital.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Radiotherapy with PD-1 inhibition followed by GM-CSF and IL-2 in advanced malignancies: a clinical study · DOI: 10.3760/cma.j.cn113030-20250923-00369
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.